Abstract
Introduction Human adenoviruses type F (HAdV-F) are leading cause of childhood diarrhoeal deaths. Genomic analysis would be key for understanding their potential drivers of disease severity, transmission dynamics, and for vaccine development. However, currently there is only limited data on HAdV-F genomes globally.
Methods Here, we sequenced and analysed HAdV-F from stool samples collected in coastal Kenya between 2013 and 2022. The samples were collected at Kilifi County Hospital in Kilifi, Kenya, from children < 13 years of age who reported a history of ≥ 3 loose stools in the previous 24hrs. The genomes were compared with data from the rest of the world by phylogenetic analysis and mutational profiling. Genotypes and lineages were assigned based on clustering on the global phylogenetic tree and from previously described nomenclature. Participant clinical and demographic data were linked to genotypic data.
Results Of 91 cases identified using real-time PCR, 83 near-complete genomes were assembled, and these classified into HAdV-F40 and F41. These genotypes cocirculated throughout the study period. Three and four distinct lineages were observed for HAdV-F40 (Lineage 1-3) and F41 (Lineage 1, 2A, 3A, 3C and 3D). Genotype F40 and F41 coinfections were observed in five samples, and F41 and B7 in one sample. Two children with F40 and 41 coinfections were also infected with rotavirus and had moderate and severe disease, respectively. Intratypic recombination was found in 4 HAdV-F40 sequences occurring between lineages 1 and 3. None of the HAdV-F41 cases had jaundice.
Interpretation This study provides evidence of extensive genetic diversity, coinfections and recombination within HAdV-F40 in a high adenovirus transmission setting that will inform public health policy, vaccine development that includes the locally circulating lineages, and molecular diagnostic assay development. We recommend future comprehensive studies elucidating on HAdV-F genetic diversity and immunity for rational vaccine development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by The Wellcome Trust [102975, 203077]. Dr Charles Agoti was supported by the Initiative to Develop African Research Leaders (IDeAL) through the DELTAS Africa Initiative [DEL-407 15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa Development Planning and Coordinating Agency (NEPAD Agency). The views expressed in this report are those of the authors and not necessarily those of AAS, NEPAD Agency, The Wellcome, the UK government. Dr. Charlotte J. Houldcroft was supported by funding from the Department of Genetics, University of Cambridge.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Scientific and Ethics Review Unit (SERU) at Kenya Medical Research Institute, Nairobi(SERU#CGMRC/113/3624).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the genomes were checked for the presence of all expected HAdV-F CDS and annotated using Geneious Prime 2022.2.1. The genomes were then deposited to GenBank with the following accession numbers: OP581345 - OP581409. The epidemiological data is available on the VEC dataverse (https://doi.org/10.7910/DVN/AMP10S).
